PL3240785T3 - Inhibitory drobnocząsteczkowe dehydrogenazy mleczanowej i sposoby ich wykorzystania - Google Patents

Inhibitory drobnocząsteczkowe dehydrogenazy mleczanowej i sposoby ich wykorzystania

Info

Publication number
PL3240785T3
PL3240785T3 PL15839113T PL15839113T PL3240785T3 PL 3240785 T3 PL3240785 T3 PL 3240785T3 PL 15839113 T PL15839113 T PL 15839113T PL 15839113 T PL15839113 T PL 15839113T PL 3240785 T3 PL3240785 T3 PL 3240785T3
Authority
PL
Poland
Prior art keywords
methods
small molecule
lactate dehydrogenase
molecule inhibitors
inhibitors
Prior art date
Application number
PL15839113T
Other languages
English (en)
Inventor
David J. Maloney
Ajit Jadhav
Ganesha Rai Bantukallu
Kyle Ryan BRIMACOMBE
Bryan T. Mott
Shyh Ming YANG
Daniel Jason URBAN
Xin Hu
Anton Simeonov
Jennifer L. KOUZNETSOVA
Alex Gregory Waterson
Gary Allen SULIKOWSKI
Kwangho Kim
Plamen CHRISTOV
Somnath JANA
Victor M. Darley-Usmar
Leonard M. Neckers
William J. Moore
Chi V. Dang
Original Assignee
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Vanderbilt University
The Trustees Of The University Of Pennsylvania
The Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Vanderbilt University, The Trustees Of The University Of Pennsylvania, The Uab Research Foundation filed Critical The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Publication of PL3240785T3 publication Critical patent/PL3240785T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL15839113T 2014-12-29 2015-12-29 Inhibitory drobnocząsteczkowe dehydrogenazy mleczanowej i sposoby ich wykorzystania PL3240785T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462097226P 2014-12-29 2014-12-29
EP15839113.6A EP3240785B1 (en) 2014-12-29 2015-12-29 Small molecule inhibitors of lactate dehydrogenase and methods of use thereof
PCT/US2015/067895 WO2016109559A2 (en) 2014-12-29 2015-12-29 Small molecule inhibitors of lactate dehydrogenase and methods of use thereof

Publications (1)

Publication Number Publication Date
PL3240785T3 true PL3240785T3 (pl) 2021-12-06

Family

ID=55451544

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15839113T PL3240785T3 (pl) 2014-12-29 2015-12-29 Inhibitory drobnocząsteczkowe dehydrogenazy mleczanowej i sposoby ich wykorzystania

Country Status (12)

Country Link
US (5) US10351532B2 (pl)
EP (2) EP3240785B1 (pl)
JP (3) JP6903580B2 (pl)
CN (1) CN107624112B (pl)
AU (2) AU2015374118B2 (pl)
CA (2) CA3210002A1 (pl)
DK (1) DK3240785T3 (pl)
ES (2) ES3042832T3 (pl)
HU (1) HUE055662T2 (pl)
PL (1) PL3240785T3 (pl)
SI (1) SI3240785T1 (pl)
WO (1) WO2016109559A2 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3240785T3 (pl) * 2014-12-29 2021-12-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitory drobnocząsteczkowe dehydrogenazy mleczanowej i sposoby ich wykorzystania
CA3009669C (en) * 2016-01-21 2023-08-08 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
CN109996797B (zh) * 2016-06-29 2022-07-22 美国政府健康及人类服务部 作为乳酸脱氢酶的抑制剂的1h-吡唑-1-基-噻唑及其使用方法
AU2018208422B2 (en) 2017-01-10 2021-11-11 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
SG11202001684PA (en) 2017-10-06 2020-03-30 Forma Therapeutics Inc Inhibiting ubiquitin specific peptidase 30
ES2988920T3 (es) 2018-05-17 2024-11-22 Forma Therapeutics Inc Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina
WO2020030613A1 (en) 2018-08-07 2020-02-13 Kemijski Institut Small molecule-inhibitors of 6-phosphofructo-1-kinase for reducing lactate generation by cancer cells
EP3632908A1 (en) 2018-10-02 2020-04-08 Inventiva Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer
PL3860989T3 (pl) 2018-10-05 2023-07-10 Forma Therapeutics, Inc. Sprzężone piroliny, które działają jako inhibitory proteazy 30 swoistej dla ubikwityny (usp30)
TWI820231B (zh) 2018-10-11 2023-11-01 德商拜耳廠股份有限公司 用於製備經取代咪唑衍生物之方法
CU20210042A7 (es) 2018-11-22 2022-01-13 Qilu Regor Therapeutics Inc Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
BR112021020335A2 (pt) 2019-04-12 2021-12-14 Qilu Regor Therapeutics Inc Agonistas glp-1r e usos dos mesmos
CA3138822A1 (en) * 2019-05-02 2020-11-05 Universite Catholique De Louvain Lactate dehydrogenase inhibitor polypeptides for use in the treatment of cancer
US11725026B2 (en) * 2019-06-28 2023-08-15 The Research Foundation For The State University Of New York Compositions and methods for inhibiting lactate dehydrogenase a activity
US12558424B2 (en) 2019-08-07 2026-02-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cells having enhanced anti-tumor activity
EP4153586A4 (en) * 2020-05-18 2024-07-10 Chinook Therapeutics Canada, Inc. SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE
US11752138B2 (en) 2020-05-18 2023-09-12 Vanderbilt University Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate dehydrogenase
KR20230016646A (ko) * 2020-05-18 2023-02-02 치누크 테라퓨틱스 캐나다, 인크. 치환된 피라졸릴 화합물 및 이의 사용 방법
US20230321135A1 (en) * 2020-06-08 2023-10-12 Qatar Foundation For Education, Science And Community Development Targeting of lactate dehydrogenase c, methods of preparing same, and methods of using same in combination with anti-cancer treatments
US20230247994A1 (en) 2020-07-02 2023-08-10 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
EP4255904A2 (en) * 2020-12-03 2023-10-11 Domain Therapeutics Novel par-2 inhibitors
WO2024212024A1 (en) * 2023-04-09 2024-10-17 Meta Pharmaceuticals (Hk) Limited Novel substituted pyrrole compounds, compositions comprising the substituted pyrrole compound, and methods of use thereof
WO2025011479A1 (en) * 2023-07-13 2025-01-16 Meta Pharmaceuticals (Hk) Limited Pyrazole based inhibitors of LDH and their use in immune and inflammatory diseases
WO2025026738A1 (en) 2023-07-31 2025-02-06 Bayer Aktiengesellschaft 6-[5-(ethylsulfonyl)-1-methyl-1h-imidazol-4-yl]-7-methyl-3-(pentafluoroethyl)-7h-imidazo[4,5-c]pyridazine derivatives as pesticides
WO2025241048A1 (en) * 2024-05-20 2025-11-27 Meta Pharmaceuticals (Hk) Limited Inhibitors of lactate dehydrogenase, compositions comprising the inhibitor, and methods of use thereof
WO2025241047A1 (en) * 2024-05-20 2025-11-27 Meta Pharmaceuticals (Hk) Limited Inhibitors of lactate dehydrogenase, compositions comprising the inhibitor, and methods of use thereof
WO2025241049A1 (en) * 2024-05-20 2025-11-27 Meta Pharmaceuticals (Hk) Limited Inhibitors of lactate dehydrogenase, compositions comprising the inhibitor, and methods of use thereof
CN118772058B (zh) * 2024-06-14 2026-03-17 济南尚博医药股份有限公司 一种2-氯-4-(1h-吡唑-3-基)苯甲腈的合成方法及应用

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182289A (en) 1988-06-14 1993-01-26 Schering Corporation Heterobicyclic compounds having antiinflammatory activity
US5128352A (en) * 1989-01-10 1992-07-07 Pfizer Inc. Anti-inflammatory 1-heteroaryl-oxindole-3-carboxamides
US5602113A (en) 1991-02-07 1997-02-11 Boehringer Ingelheim Pharmaceuticals, Inc. Pyridobenzo- and pyridiothieno-diazepines useful for the treatment of HIV infection
CN1071924A (zh) 1991-10-29 1993-05-12 纳幕尔杜邦公司 除草的三唑羧酸酰胺
JPH0680569A (ja) 1992-09-03 1994-03-22 Asahi Chem Ind Co Ltd 血小板凝集阻害剤
US5342851A (en) 1992-10-07 1994-08-30 Mcneil-Ppc, Inc. Substituted thiazole derivatives useful as platelet aggregation inhibitors
DE4405207A1 (de) 1994-02-18 1995-08-24 Bayer Ag N-Pyrazolylaniline und N-Pyrazolylaminopyridine
US20020028936A1 (en) 1999-04-12 2002-03-07 Gerhard Sperl 1,3-disubstituted indolin-2-ones for neoplasia
US6136079A (en) 1999-04-30 2000-10-24 Eastman Kodak Company Dye for ink jet ink
AU5960300A (en) 1999-07-15 2001-02-05 Nps Allelix Corp. Heterocyclic compounds for the treatment of migraine
US6407238B1 (en) 1999-10-29 2002-06-18 Boehringer Ingelheim Pharmaceuticals, Inc. Process of making substituted pyrazoles
US6436965B1 (en) 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
JP2002167531A (ja) 2000-11-29 2002-06-11 Fuji Photo Film Co Ltd インクジェット記録用インク組成物及び画像形成方法
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
AU2002352148A1 (en) 2001-06-29 2003-03-03 Abbott Gmnh & Co. Kg Bis-aryl thiazole derivatives
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
AU2003256297A1 (en) 2002-08-09 2004-02-25 Eli Lilly And Company Benzimidazoles and benzothiazoles as inhibitors of map kinase
AU2003265395A1 (en) 2002-08-14 2004-03-03 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
WO2004043913A2 (en) 2002-11-08 2004-05-27 Trimeris, Inc. Hetero-substituted benzimidazole compounds and antiviral uses thereof
CA2520804A1 (en) 2003-04-03 2004-10-28 Merck & Co., Inc. Biaryl substituted pyrazoles as sodium channel blockers
GB0323845D0 (en) 2003-10-10 2003-11-12 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
US7387980B2 (en) 2004-09-22 2008-06-17 Symyx Technologies, Inc. Methods of using heterocycle-amine ligands, compositions, complexes, and catalysts
WO2006052546A2 (en) 2004-11-04 2006-05-18 Neurogen Corporation Pyrazolylmethyl heteroaryl derivatives
JP2008527030A (ja) 2005-01-19 2008-07-24 バイオリポックス エービー 炎症の治療に有用なインドール類
US20090042949A1 (en) 2005-01-19 2009-02-12 Benjamin Pelcman Indoles Useful in the Treatment of Inflammation
WO2006077401A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Pyrrolopyridines useful in the treatment of inflammation
ATE501119T1 (de) 2005-01-19 2011-03-15 Biolipox Ab Entzündungshemmende indol-derivate
US20080249091A1 (en) 2005-01-19 2008-10-09 Benjamin Pelcman Indoles Useful in the Treatment of Inflammation
US20080132510A1 (en) 2005-01-21 2008-06-05 Bingsong Han Imidazolylmethyl and Pyrazolylmethyl Heteroaryl Derivatives
GB0507198D0 (en) 2005-04-08 2005-05-18 Sb Pharmco Inc Process for preparing bicyclic compounds
US7456292B2 (en) 2005-06-30 2008-11-25 Bexel Pharmaceuticals, Inc. Hydroxamic acid-containing amino acid derivatives
WO2007018514A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2007018508A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetycholine receptor antagonists
CA2620179C (en) 2005-08-16 2013-10-29 Icagen, Inc. Inhibitors of voltage-gated sodium channels
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
AU2006298563A1 (en) 2005-10-06 2007-04-12 Merck & Co., Inc. Use of fused pyrrole carboxylic acids for the treatment of neurodegenerative and psychiatric diseases as D-amino acid oxidase inhibitors
WO2007045386A1 (en) 2005-10-17 2007-04-26 Isagro Ricerca S.R.L. Compounds and relative use for the control of phytopathogens
WO2007048732A1 (de) 2005-10-28 2007-05-03 Basf Aktiengesellschaft Verwendung von 5-amino-pyrazolen zur bekämpfung pflanzenpathogener schadpilze, neue 5-amino-pyrazole, verfahren zu ihrer herstellung und sie enthaltende mittel
EP1998766A2 (en) 2005-12-16 2008-12-10 Ironwood Pharmaceuticals, Inc. Useful indole compounds
ITMI20052459A1 (it) 2005-12-22 2007-06-23 Isagro Spa Sali quaternari e relativo uso per il controllo di fitopatogeni
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
GB0614068D0 (en) * 2006-07-14 2006-08-23 Glaxo Group Ltd Compounds
WO2008009924A2 (en) 2006-07-18 2008-01-24 Biolipox Ab Indoles useful in the treatment of inflammation
US7906544B2 (en) 2007-01-26 2011-03-15 North Carolina State University Inhibition of bacterial biofilms with imidazole derivatives
WO2008121861A2 (en) 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Pyrazole and pyrrole compounds useful in treating iron disorders
AR068063A1 (es) 2007-08-27 2009-11-04 Basf Plant Science Gmbh Co mpuestos de pirazol para controlar plagas de invertebrados
US8389567B2 (en) 2007-12-12 2013-03-05 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2009108551A2 (en) 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
WO2009137291A2 (en) 2008-05-08 2009-11-12 Merck & Co., Inc. Spiroazaindoles
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
JPWO2010007944A1 (ja) * 2008-07-17 2012-01-05 旭化成ファーマ株式会社 含窒素二環性複素環化合物
JPWO2010007943A1 (ja) * 2008-07-17 2012-01-05 旭化成ファーマ株式会社 含窒素複素環化合物
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010034737A1 (en) 2008-09-24 2010-04-01 Basf Se Pyrazole compounds for controlling invertebrate pests
EP2358266A4 (en) * 2008-11-20 2012-10-03 Bodymedia Inc METHOD AND DEVICE FOR DETERMINING CRITICAL CARE PARAMETERS
EP2367798B1 (en) * 2008-11-20 2018-02-28 Northwestern University Pyrazolone derivatives useful in the treatment of amyotrophic lateral sclerosis
CN101747276B (zh) 2008-11-28 2011-09-07 中国中化股份有限公司 具有含氮五元杂环的醚类化合物及其应用
KR101371881B1 (ko) 2008-12-04 2014-03-07 에프. 호프만-라 로슈 아게 피리다진온 유도체
WO2010075376A2 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
ES2660892T3 (es) 2009-03-23 2018-03-26 Merck Sharp & Dohme Corp. Antagonistas del receptor P2X3 para el tratamiento del dolor
CA2758071C (en) 2009-04-06 2018-01-09 Agios Pharmaceuticals, Inc. Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
WO2011057942A1 (en) 2009-11-12 2011-05-19 Basf Se Insecticidal methods using pyridine compounds
EP2516437B1 (en) 2009-12-21 2014-01-29 Novartis AG Disubstituted heteroaryl-fused pyridines
WO2011091410A1 (en) 2010-01-25 2011-07-28 Glaxos Smithkline Llc Trpv4 antagonists
EP2638012A1 (en) 2010-11-10 2013-09-18 Boehringer Ingelheim International GmbH Pyridyl ureas as mineralocorticoid receptor antagonists
JPWO2012074022A1 (ja) 2010-12-01 2014-05-19 旭硝子株式会社 イリジウムカチオン錯体および発光組成物
AR084515A1 (es) 2010-12-22 2013-05-22 Merz Pharma Gmbh & Co Kgaa Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras
JP2014506915A (ja) 2011-03-04 2014-03-20 ノバルティス アーゲー キナーゼ阻害剤としての四置換シクロヘキシル化合物
US9181231B2 (en) 2011-05-03 2015-11-10 Agios Pharmaceuticals, Inc Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
EP2704701B1 (en) 2011-05-03 2018-01-03 PRCL Research Inc. Compounds for inflammation and immune-related uses
WO2012154880A1 (en) 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases
JP2013040240A (ja) 2011-08-11 2013-02-28 Fujifilm Corp アゾ化合物、アゾ顔料、顔料分散物、着色組成物、カラーフィルター用着色組成物、カラーフィルター、カラーフィルター用着色組成物の調製方法、インクジェット記録用インク、印刷インク、塗料、染料、及び、レジストインク
WO2013027801A1 (ja) 2011-08-24 2013-02-28 キッセイ薬品工業株式会社 縮合へテロ環誘導体及びその医薬用途
ITPI20110143A1 (it) * 2011-12-20 2013-06-21 Univ Pisa Agenti terapeutici in grado di ridurre la produzione cellulare di acido lattico e composizioni farmaceutiche che comprendono tali composti
CA2863517C (en) 2012-01-20 2019-11-05 Genosco Substituted pyrimidine compounds and their use as syk inhibitors
AU2013297601B2 (en) 2012-07-30 2017-02-16 Taisho Pharmaceutical Co., Ltd. Partially saturated nitrogen-containing heterocyclic compound
WO2014062938A1 (en) 2012-10-19 2014-04-24 Bristol-Myers Squibb Company Rory modulators
WO2014099697A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. 3-ester-4-substituted orexin receptor antagonists
EP2934527A4 (en) 2012-12-20 2016-07-13 Merck Sharp & Dohme 2-pyridyloxy-4-ESTER-orexin receptor antagonists
US9643955B2 (en) 2012-12-20 2017-05-09 Merck Sharp & Dohme Corp. 2-pyridyloxy-3-nitrile-4-substituted orexin receptor antagonists
FR3001219A1 (fr) 2013-01-22 2014-07-25 Centre Nat Rech Scient Inhibiteurs de kinases
US9522876B2 (en) 2013-03-15 2016-12-20 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US10468610B2 (en) 2013-03-29 2019-11-05 Konica Minolta, Inc. Isomer-mixture metal complex composition, organic electroluminescent element, illuminator, and display device
WO2014173880A1 (en) 2013-04-22 2014-10-30 Syngenta Participations Ag Novel microbiocides
WO2014176475A2 (en) 2013-04-26 2014-10-30 The Regents Of The University Of Michigan Egfr inhibitors and uses thereof
US9169221B2 (en) 2013-04-29 2015-10-27 Comsats Institute Of Information Technology Dihydro 1,4-benzoxazines and method of synthesizing the same using sulfonium salts
PL3240785T3 (pl) * 2014-12-29 2021-12-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitory drobnocząsteczkowe dehydrogenazy mleczanowej i sposoby ich wykorzystania

Also Published As

Publication number Publication date
JP7771139B2 (ja) 2025-11-17
JP2018503631A (ja) 2018-02-08
EP3954685B1 (en) 2025-08-27
CA2978823C (en) 2023-10-10
US20220220078A1 (en) 2022-07-14
JP2021152064A (ja) 2021-09-30
US20240368087A1 (en) 2024-11-07
US12365653B2 (en) 2025-07-22
US10351532B2 (en) 2019-07-16
US20200002285A1 (en) 2020-01-02
CN107624112B (zh) 2022-03-04
WO2016109559A2 (en) 2016-07-07
DK3240785T3 (da) 2021-09-27
EP3240785A2 (en) 2017-11-08
JP2023153302A (ja) 2023-10-17
AU2020257163B2 (en) 2022-06-30
CA3210002A1 (en) 2016-07-07
WO2016109559A3 (en) 2016-08-25
SI3240785T1 (sl) 2021-11-30
ES2883938T3 (es) 2021-12-09
AU2015374118B2 (en) 2020-07-23
JP6903580B2 (ja) 2021-07-14
ES3042832T3 (en) 2025-11-24
US20210323928A1 (en) 2021-10-21
US10961200B2 (en) 2021-03-30
EP3954685A1 (en) 2022-02-16
AU2020257163A1 (en) 2020-11-19
EP3240785B1 (en) 2021-07-07
US11247971B2 (en) 2022-02-15
JP7337883B2 (ja) 2023-09-04
CN107624112A (zh) 2018-01-23
AU2015374118A1 (en) 2017-07-20
US20180273488A1 (en) 2018-09-27
HUE055662T2 (hu) 2021-12-28
CA2978823A1 (en) 2016-07-07
US11897845B2 (en) 2024-02-13

Similar Documents

Publication Publication Date Title
HUE055662T2 (hu) Laktát-dehidrogenáz kismolekulás inhibitorai és alkalmazási eljárásai
IL285154A (en) Therapeutic inhibitor of lactate dehydrogenase and their factors
IL250415B (en) Antibodies against pd-l and methods of using them
EP3160498A4 (en) Il-15-based molecules and methods of use thereof
ZA201605639B (en) Hppd variants and methods of use
IL259801A (en) ezh2 inhibitors and methods of using them
PL3218005T3 (pl) Związki oddziałujące z glikanami i sposoby ich zastosowania
GB201418350D0 (en) Dispenser and methods of use thereof
PL3089971T3 (pl) Związki i sposoby ich zastosowania
ZA201606243B (en) Hppd variants and methods of use
EP3226955A4 (en) Self-anchoring catheters and methods of use
EP3177327A4 (en) Inhibitors of myh7b and uses thereof
EP3190886A4 (en) Compositions and methods of use thereof
SG11201509738RA (en) Methods of treatment and compositions with xanthine oxidase inhibitors
EP3137873A4 (en) Viscometer and methods of use thereof
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
EP3134108A4 (en) Agents and methods of treatment
ZA201606450B (en) Compounds and their methods of use
IL266344A (en) Inhibitors of mtor-deptor interactions and methods of use thereof
EP3207029A4 (en) Tryptamide compositions and methods of use
SG11201704108YA (en) Methods of processing including peeling
EP3142999A4 (en) Methods and compositions of dasotraline for treatment of adhd
GB201417248D0 (en) Compostion and methods of treatment
EP3236966A4 (en) Combination of raf inhibitors and taxanes
GB201403697D0 (en) Compounds and methods of use